Selling, General, and Administrative Costs: Pharming Group N.V. vs ADMA Biologics, Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Pharming Group N.V. and ADMA Biologics, Inc. from 2014 to 2023. Over this period, Pharming Group N.V. consistently outspent ADMA Biologics, Inc., with its SG&A expenses peaking at approximately 132% higher than ADMA's in 2022.

Key Insights

• 2014-2016: Both companies maintained relatively low SG&A expenses, with ADMA Biologics, Inc. showing a steady increase of around 76% over these years.
• 2017-2020: Pharming Group N.V. saw a significant rise, with expenses more than doubling, reflecting strategic investments or expansions.
• 2021-2023: While ADMA Biologics, Inc. increased its expenses by 38%, Pharming Group N.V. experienced fluctuations, indicating possible shifts in business strategy.

Understanding these trends provides valuable insights into each company's operational strategies and market positioning.